跳至主要内容
临床试验/NL-OMON40981
NL-OMON40981已完成2 期

An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy - The effect of EST on GERD after sleeve gastrectomy

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • a. Subject is between 18 * 80 years of age.
  • b. Subject underwent a sleeve gastrectomy minimum one year prior to enrollment (in order to have reached a stable weight loss plateau).
  • c. Subject has a history of heartburn, regurgitation or both for >6 month prompting physician recommendation of continual daily use of PPI after sleeve gastrectomy.
  • d. Baseline off-PPI GERD-HRQL score * 20 following 10-14 days off PPI
  • e. Baseline off-PPI GERD-HRQLscore is at least 5 points higher than the on-PPI score or a positive relationship between the occurrence of their primary symptom during the pH impedance monitoring (symptom association probability * 95% or a SI score * 50%) is present.
  • f. Subject who are on standard medical therapy for 6 months or longer and experience discomfort or who are otherwise dissatisfied with GERD symptoms.
  • g. Subjects with a GERD condition that in the opinion of the PI justifies a minimally invasive reversible procedure prior to attempting a more drastic procedure such as a gastric bypass.
  • h. Subject has exhibited excessive lower esophageal acid exposure during 24-hour pH-metry of antisecretory therapy performed within 6 months of screening visit; pH < 4 for > 6% of total time.
  • i. Subject has a resting LES end expiratory pressure * 5mmHg on manometry performed within 6 months of enrollment.
  • j. Subject has no esophagitis or esophagitis * Grade C (LA classification) on upper endoscopy within 6 months of enrollment.
  • k. Subject has esophageal body contraction amplitude > 30 mmHg for >30% of swallows and > 30% peristaltic contractions on manometry.
  • l. Subject has signed the informed consent form and is able to adhere to study visit schedule.

排除标准

  • a. Subject has any non-GERD esophageal motility disorders.
  • b. Subject has evidence of obstruction or stricture in the gastric sleeve by a barium swallow and endoscopy.
  • c. Subject has any significant multisystem diseases.
  • d. Subject has an autoimmune or a connective tissue disorder (e.g. scleroderma, dematomyositis, Calcinosis-Raynaud*s-Esophagus Sclerodactyly Syndrome (CREST), Sjogren*s Syndrome, Sharp*s Syndrome) requiring therapy in the preceding 2 years.
  • e. Subject has Barrett*s epithelium (> M2; >C1) or any grade of dysplasia.
  • f. Subject has a hiatal hernia larger than 3 cm.
  • g. Subject has a body mass index (BMI) greater than 35 kg/m2.
  • h. Subject has Type 1 Diabetes Mellitus
  • i. Subject has uncontrolled Type 2 Diabetes Mellitus (T2DM) defined as HbA1c >9.5 in the previous 6 months, or has T2DM for > 10 years.
  • j. Subject has a history of suspected or confirmed esophageal or gastric cancer.
  • k. Subject has esophageal or gastric varices.
  • l. Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease.
  • m. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
  • n. Subject requires chronic anticoagulant therapy.
  • o. Subject has dysphagia or esophageal peptic stricture, excluding Schatzki*s ring.
  • p. Subject of child-bearing potential who is pregnant or intends to become pregnant during the trial period.
  • q. Subject is currently enrolled in other potentially confounding research.
  • r. History of any malignancy in the last 2 years.
  • s. Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.
  • t. Weight change of +/- 10% of the EWL (Excess Weight Loss) in the 3 months prior to enrollment.

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验